---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015526"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:27:36.129852+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Armata Pharma Q3 net loss $5.5M; Phase 2 Tail wind enrolled, topline data expected by year-end

## Summary
- Net loss $5.5M ($0.15/share) vs $31.2M loss in Q3 2023; includes $6.9M non-cash gain on convertible debt.
- Grant revenue $3.0M (DoD/MTEC) vs $1.2M; R&D expense $9.5M; cash $17.1M as of Sep 30, 2024.
- Phase 2 Tail wind (inhaled AP-PA02 for NCFB) enrollment complete; topline data expected by year-end 2024.
- Phase 1b/2a diSArm (IV AP-SA02 for S. aureus bacteremia) enrollment complete; topline data Q1 2025.
- Extended convertible debt and credit agreement maturity to Jan 10, 2026; appointed David House SVP Finance.

## SEC filing metadata
- accession: 0001558370-24-015526
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000155837024015526/0001558370-24-015526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000155837024015526/armp-20241113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015526
- JSON: https://secwatch.observer/filing/0001558370-24-015526.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.